BD sees Q1 revenues up 26% as COVID-19 testing drives sales

By LabPulse.com staff writers

January 13, 2021 -- Becton Dickinson (BD) is projecting revenues for its fiscal first quarter to grow 26% as sales of COVID-19 testing products hit $865 million -- contributing 20 percentage points to revenue growth for the quarter.

For the first quarter (end-December 31), BD is projecting sales of $5.3 billion, up 25.6% compared to the same period of fiscal 2020, and up 24.2% after currency adjustments. The company said it saw sales of $865 million from COVID-19 testing sales, of which $685 million consisted of sales of its BD Veritor product.

In the company's BD Medical segment, first-quarter revenues are expected to hit $2.3 billion, an increase of 7% after currency adjustments, while in its BD Life Sciences segment, the firm expects sales of $2.0 billion, a 74.2% increase after currency adjustments. This segment includes the company's COVID-19 testing business.


Copyright © 2021 LabPulse.com
 

To read this and get access to all of the exclusive content on LabPulse.com, create a free account or sign in now.

Member Sign In:
MemberID or email address:  
Do you have a LabPulse.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?